ELINZANETANT - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for elinzanetant and what is the scope of freedom to operate?
Elinzanetant
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for ELINZANETANT
| International Patents: | 115 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 18 |
| Patent Applications: | 62 |
| What excipients (inactive ingredients) are in ELINZANETANT? | ELINZANETANT excipients list |
| DailyMed Link: | ELINZANETANT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ELINZANETANT
Generic Entry Date for ELINZANETANT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ELINZANETANT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bayer | PHASE1 |
| Bayer | Phase 2 |
| Bayer | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for ELINZANETANT
US Patents and Regulatory Information for ELINZANETANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | LYNKUET | elinzanetant | CAPSULE;ORAL | 219469-001 | Oct 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Hlthcare | LYNKUET | elinzanetant | CAPSULE;ORAL | 219469-001 | Oct 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Hlthcare | LYNKUET | elinzanetant | CAPSULE;ORAL | 219469-001 | Oct 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Hlthcare | LYNKUET | elinzanetant | CAPSULE;ORAL | 219469-001 | Oct 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ELINZANETANT
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2016264034 | ⤷ Start Trial | |
| Australia | 2020201074 | ⤷ Start Trial | |
| Brazil | 112017024852 | ⤷ Start Trial | |
| Canada | 2984591 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ELINZANETANT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3297631 | 50006/2026 | Austria | ⤷ Start Trial | PRODUCT NAME: ELINZANETANT; REGISTRATION NO/DATE: EU/1/25/1991 (MITTEILUNG) 20251118 |
| 3297631 | LUC50035 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ELINZANETANT; AUTHORISATION NUMBER AND DATE: EU/1/25/1991 20251118 |
| 3297631 | 301384 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ELINZANETANT; REGISTRATION NO/DATE: EU/1/25/1991 20251118 |
| 3297631 | C20260003 | Finland | ⤷ Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
